Tailored Surgical Therapy for Acute Native Mitral Valve Endocarditis Tomislav Mihaljevic MD, Subroto Paul MD, Marzia Leacche MD, James
D. Rawn MD, Sary Aranki MD, Patrick T. O’Gara MD1, Lawrence H.
Cohn MD, John G. Byrne MD |
|||||||
Background and aim of the study: Mitral valve
repair has been shown superior to valve replacement for the treatment
of non-infectious valve disease. The criteria and results of valve repair
for native valve endocarditis are still being defined. The study aim
was to examine the short- and long-term results of mitral valve repair
and replacement for acute infective endocarditis and to define criteria
for the use of each technique. |
(p = 0.14). Median follow up was 4 years (range: 6-108 months).
At five years follow up, a median ejection fraction (EF) of 60% and mitral
regurgitation (MR) grade of 1/4 was observed, with an overall late survival
of 85% (19/21), in the repair group, while the replacement group had a
median EF of 55% and an overall late survival of 73% (p = 0.73). Recurrent
endocarditis occurred in 2/21 (10%) in the repair group and 1/32 (3%) in
the replacement group (p = 0.34). Conclusion: Mitral valve repair is a safe and effective technique to treat acute native mitral valve infective endocarditis with favorable short- and long-term morbidity and mortality. Patients with advanced endocarditis and annular destruction require valve replacement. Mitral valve repair should be performed when technically feasible. |
||||||
|
|||||||